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Background: Assessment of airway inﬂ  ammation in the clinical course of acute exacerbations 
of chronic obstructive pulmonary disease (AECOPD) may advance our understanding of the 
pathogenesis and treatment.
Objectives: To assess airway inﬂ  ammation in patients during the course of AECOPD by serial 
analyses of their exhaled breath condensates (EBC).
Methods: Twenty-six patients with AECOPD (22 males, mean[SD] percentage predicted forced 
expiratory volume in one second (FEV1) 44.8 [14.3]), 11 with stable COPD, and 14 age and 
sex-matched healthy controls were studied. Patients with AECOPD were treated with systemic 
steroid and antibiotic for 7 days. EBC was collected from each patient with AECOPD on Day 
5, 14, 30, and 60 post-hospitalization using EcoScreen (VIASYS Healthcare, USA) during tidal 
breathing over 10 minutes. Concentrations of tumor necrosis factor-α (TNF-α), leukotriene 
B4 (LTB4), and interleukin-8 (IL-8) were measured by enzyme-linked immunosorbent assay.
Results: The median (IQR) of TNF-α level on Day 5 was 5.08 (3.80–6 .32) pg/ml, which was 
lower than on Day 14 (5.84 [4.91–9.14] pg/ml, p = 0.017), Day 30 (6.14 [3.82–7.67] pg/ml, 
p = 0.045), and Day 60 (5.60 [4.53–8.80] pg/ml, p = 0.009). On Day 60, subjects receiving inhaled 
corticosteroid (ICS) had a lower level of TNF-α than those who were not (4.82 [4.06–5.65] vs 
7.66 [5.48–10.9] pg/ml, p = 0.02). EBC LTB4  level did not change signiﬁ  cantly during recovery 
from AECOPD whereas IL-8 was mostly undetectable.
Conclusions: EBC TNF-α level was low in patients receiving systemic steroid and antibiotic 
therapy for AECOPD. These ﬁ  ndings suggest a potential role for serial EBC TNF-α for non-
invasive monitoring of disease activity.
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Background
Assessment of airway inﬂ  ammation in the clinical course of acute exacerbations of 
chronic obstructive pulmonary disease (AECOPD) may advance our understanding of 
the pathogenesis and the treatment effects in patients with AECOPD. Exhaled breath 
condensate (EBC) analysis has been developed in recent years as a novel tool to sample 
the lower airway lining ﬂ  uid (Effros et al 2004; Hunt 2002; Montuschi and Barnes 
2002; Ko et al 2007). Its noninvasive nature offers many advantages over invasive 
techniques such as bronchoalveolar lavage, bronchial biopsy and sputum induction, 
which are not so well tolerated by AECOPD patients. Because of the noninvasive nature 
of EBC collection, repeated measurements are feasible in the longitudinal follow-up 
of patients with AECOPD. Our group has previously demonstrated the repeatability of 
certain markers in the EBC of stable asthma and COPD patients (Ko et al 2006; Ko 
et al 2006; Leung et al 2005).International Journal of COPD 2009:4 80
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Tumor necrosis factor-α (TNF-α) is a pleiotropic 
inﬂ  ammatory cytokine produced by many different cell types. 
The main sources in vivo are stimulated monocytes, ﬁ  broblasts, 
and endothelial cells (Mukhopadhyay et al 2006). Leukotriene 
B4 (LTB4) is a potent chemoattractant of neutrophils, and it 
may be released by macrophages, epithelial cells and acti-
vated neutrophils (Ford-Hutchinson et al 1980). Interleukin 8 
(IL-8), on the other hand, is largely produced by neutrophils 
and macrophages (Baggiolini et al 1989). Previous studies 
found signiﬁ  cant increases in neutrophils and concentrations 
of TNF-α and IL-8 in spontaneous or induced sputum samples 
from patients with COPD when compared to smoking and non-
smoking controls (Keatings et al 1996; Yamamoto et al 1997). 
During AECOPD, the concentrations of TNF-α and IL-8 may 
increase further in the induced sputum samples (Aaron et al 
2001). In patients having AECOPD related to bacterial infec-
tion, increases in the concentration of neutrophil products such 
as myeloperoxidase and elastase, and the neutrophil chemoat-
tractants (IL-8 and LTB4) have been observed in expectorated 
sputum, and their levels fell subsequently after antibiotic 
therapy (Crooks et al 2000). Limited data, however, are avail-
able on the changes in the EBC levels of TNF-α, LTB4, and 
IL-8 during AECOPD. This study aimed to assess the levels 
of these inﬂ  ammatory mediators during the course of recovery 
from AECOPD by serial analyses of EBC.
Material and methods
Subject recruitment
Patients who had been admitted to the Prince of Wales Hospital 
with AECOPD were recruited for this study. AECOPD was 
deﬁ  ned when a patient with background COPD (National 
Heart, Lung and Blood Institute, World Health Organiza-
tion 2006) presented with at least two of the following major 
symptoms (increased dyspnoea, increased sputum purulence, 
increased sputum volume) or one major and one minor symp-
tom (nasal discharge/congestion, wheeze, sore throat, cough) 
for at least two consecutive days (Seemungal et al 1998; Patel 
et al 2002; Ko et al 2007). Subjects with pneumonic changes 
on the chest radiographs were excluded. Age and sex-matched 
COPD subjects who were clinically stable (without AECOPD 
for at least 10 weeks) and healthy, nonsmoking subjects were 
recruited as controls. Patients with AECOPD were managed 
by our standard care with administration of antibiotic (oral 
amoxicillin/clavulanic acid for 7 days) and systemic steroid 
(oral prednisolone 30mg daily for 7 days). All patients also 
received bronchodilators via a spacer device and if needed, 
oxygen therapy for respiratory failure. Current smokers (deﬁ  ned 
as cigarette smoking in the last 6 months) were excluded from 
this study. Informed written consent was obtained from each 
subject and the study was approved by the research ethics com-
mittee of the Chinese University of Hong Kong.
Collection of exhaled breath condensate
EBC was collected using the EcoScreen (VIASYS Healthcare, 
Conshohochen, PA, USA) according to the manufacturer’s 
instructions. The collection was carried out from 9–10 am. 
After rinsing their mouths, the recruited subjects breathed tidally 
through a mouthpiece that was connected through a unique one-
way valve into a cooled collection tube where vapors, aerosols 
and moisture in the breath condensed along the walls of the tube. 
The design of the system prevented salivary contamination of 
EBC. Each subject was asked to breathe through the device, 
while wearing a nose-clip, for 10 minutes, and more than 1 mL 
of EBC could be collected from each subject. EBC was stored 
in 250 μL aliquots immediately at −70 oC until analysis. EBC 
was collected on Days 5, 14, 30, and 60 after hospitalization 
for subjects with AECOPD. For the stable COPD patients and 
normal controls, EBC collection was performed once.
Lung function measurement
Spirometry (post-bronchodilator) was performed on all 
subjects before each EBC collection with the Vitalograph 
(Model S, Buckingham, UK) spirometer according to the 
American Thoracic Society standards (American Thoracic 
Society. Standardization of spirometry – 1987). The updated 
predicted spirometry values for Hong Kong Chinese were 
adopted (Ip et al 2006).
Measurement of TNF-α, LTB4, and IL-8
The concentrations of TNF-α, LTB4, and IL-8 in EBC were 
measured in one batch by high-sensitivity sandwich enzyme 
immunoassays (TNF-α and IL-8 from BioSource International, 
Camarillo, CA, USA; LTB4 from Cayman Chemical Com-
pany, Ann Arbor, MI, USA) according to the manufacturers’ 
instructions. The detection limits of TNF-α, LTB4, and IL-8 
were 0.09, 4, and 0.02 pg/mL, respectively, and the intra-assay 
and inter-assay variability of all three markers were  10%.
Intra-subject repeatability of TNF-α, LTB4, and 
IL-8 was assessed by collection of EBC in 6 stable COPD 
subjects. EBC was collected as described above at the same 
time (9–10 am) on 2 consecutive days.
Statistical analysis
Data were analyzed by the Statistical Package of the Social 
Science (SPSS) for Windows, Version 11.5 (SPSS Inc, Chicago, 
IL, USA). Demographic data of the subjects were presented International Journal of COPD 2009:4 81
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as means ± standard deviation (SD). The levels of TNF-α, 
LTB4, and IL-8 were expressed as median and interquartile 
range (IQR). When the levels of these biomarkers were below 
the respective detection limits of the assays, the samples were 
assigned values at half of the lower detection limits for statistical 
analysis. Results were analyzed by two-tailed Students t-test or 
ANOVA for parametric variables and Mann-Whitney U-test or 
Kruskal-Wallis test for nonparametric numerical variables. The 
serial changes of TNF-α, LTB4, and IL-8 levels were compared 
at the different time points post-admission for AECOPD by 
Wilcoxon Signed Ranks test and Friedman test as appropriate. 
Correlation of lung function with the levels of EBC markers 
were assessed by Spearman’s rank correlation test. The p values 
of  0.05 were considered as statistically signiﬁ  cant. Bland and 
Altman’s method was used to assess repeatability of TNF-α, 
LTB4, and IL-8 in the EBC (Bland and Altman 1986).
Results
Altogether 32 patients with AECOPD were initially recruited 
for this study. Two patients refused to return for EBC col-
lection after Day 14 whereas 4 patients had another exac-
erbation before Day 60 and thus were excluded from the 
study. Finally, 26 subjects with AECOPD, 11 stable COPD 
patients, and 14 controls were included in the analysis. The 
demographics of the subjects are shown in Table 1. The 
AECOPD, stable COPD and control subjects were age and 
sex-matched. Twelve (46.1) and 5 (45.5%) subjects with 
AECOPD and stable COPD were on inhaled corticosteroid 
(ICS) whereas the median (IQR) beclomethasone-equivalent 
doses were 1000 (950–2000) and 1000 (1000–1500) μg/day, 
respectively. None were on long term home oxygen therapy 
or oral steroid therapy when stable.
The detection rates of TNF-α, LTB4, and IL-8 in EBC 
of the subjects are shown in Table 2. The EBC levels 
of TNF-α and LTB4 are summarized in Table 3. The 
level of TNF-α in EBC was the lowest on Day 5 post-
hospitalization after commencement of treatments with 
both systemic steroid and antibiotic. The levels of TNF-α 
at Day 5 was signiﬁ  cantly lower than at Day 14 (p = 0.017), 
Day 30 (p = 0.045) and Day 60 (p = 0.009). There was 
however no signiﬁ  cant difference in the levels of TNF-α 
between Day 14, Day 30, and Day 60 (p = 0.89). The level 
of TNF-α at Day 14 post-hospitalization for AECOPD was 
signiﬁ  cantly higher than the normal controls (p = 0.036), 
but not different from the stable COPD subjects (p = 0.26). 
The EBC TNF-α level at the start of exacerbation (Day 5 
post-exacerbation) was not signiﬁ  cantly different from that 
during stable COPD (p = 0.39). There was no difference 
in the TNF-α level between the stable COPD and normal 
controls (p = 0.41). Figure 1 illustrates the serial levels of 
TNF-α during the course of AECOPD versus TNF-α levels 
for stable COPD and control subjects based on their single 
EBC collection.
The levels of LTB4 on Day 5, Day 14, Day 30, and Day 60 
of AECOPD showed no statistically signiﬁ  cant difference. 
In addition, there was no difference in the level of LTB4 at 
the different time points of the AECOPD when compared 
to the stable COPD patients or normal controls. IL-8 was 
Table 1 Clinical characteristics of the subjects
COPD patients with acute 
exacerbations (n = 26)
Stable COPD subjects (n = 11) Normal controls (n = 14)
Age (yrs) 73.1 ± 7.6 74.4 ± 4.9 75.2 ± 4.1
Sex (M/F) 22/6 8/3 9/5
Smoking history (pack years) 40.1 ± 20.9 41.3 ± 10.5 0
Body mass index (kg/m2) 22.1 ± 4.1 22.8 ± 5.1 22.5 ± 2.2
FEV1 (L)* 0.91 ± 0.36 0.94 ± 0.38 2.00 ± 0.41
FVC (L)* 1.74 ± 0.62 1.69 ± 0.70 2.57 ± 0.47
FEV1/FVC (%)* 53.9 ± 11.5 57.6 ± 11.7 77.8 ± 2.7#
FEV1 (% predicted)* 44.8 ± 14.3 49.4 ± 19.6 104.1 ± 17.0#
FVC (% predicted)* 62.0 ± 18.7 62.5 ± 21.4 96.9 ± 12.3#
Current ICS use 12 (46.1) 5 (45.5) 0 (0)
Current theophylline use 7 (26.9) 4 (36.4) 0 (0)
Notes: Data were presented as mean ± SD or number (%); *for the COPD patients with acute exacerbation, the lung function (post-bronchodilator) at Day 60 after 
admission to hospital was presented; #FEV1% predicted, FVC % predicted and FEV1/FVC ratio were higher in the normal controls when compared to COPD patients with 
acute exacerbations and stable COPD patients, p   0.001.
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; ICS, inhaled corticosteroid; SD, 
standard deviation.International Journal of COPD 2009:4 82
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undetectable in most of the subjects and thus their results 
were not presented.
The levels of TNF-α and LTB4 did not correlate with the 
absolute and normal predicted values of forced expiratory 
volume in one second (FEV1) at different time points of 
AECOPD. The levels of TNF-α and LTB4 on Day 60 post-
hospitalization showed no signiﬁ  cant difference in their levels 
when comparing those with FEV1   50% against those with 
FEV1   50% predicted normal, whereas the same observation 
was made among the stable state COPD subjects. On Day 
60 post-hospitalization for AECOPD, subjects receiving ICS 
therapy had a lower level of TNF-α than those who were not 
on ICS (median [IQR] 4.82 [4.06–5.65] vs 7.66 [5.48–10.9] 
pg/ml, p = 0.02). The ICS was started before AECOPD and 
continued throughout the study. For those patients who 
were not on ICS before AECOPD, ICS was not introduced 
during the study period. The reduction of TNF-α as noted in 
the AECOPD patients on ICS, however, was not observed 
in the stable COPD patients, who had no change in their 
medications for 8 weeks before recruitment into this study. 
With reference to LTB4, there was no difference in its levels 
between patients on ICS and those without ICS therapy for 
both the AECOPD subjects at Day 60 post-exacerbation and 
the stable COPD subjects.
The results of serial spirometry are shown in Table 4. 
There were no signiﬁ  cant changes in the subjects’ lung 
function in the course of AECOPD. Six stable COPD 
subjects (5 males) aged 66 to 74 years had EBC collected 
and measured for repeatability testing of the biomarkers. 
For TNF-α and LTB4 repeatability testing, the differences 
between most of the paired measurements laid within ± 2SDs 
(mean differences −0.19 ± 2.01, −0.83 ± 2.23 pg/ml for 
TNF-α and LTB4, respectively). Bland and Altman’s plots 
of the repeatability tests for TNF-α and LTB4 are shown in 
Figure 2. IL-8 was only measurable in 1 of the 6 subjects 
and thus the results are not presented.
Discussion
To the best of our knowledge, this study is the ﬁ  rst to assess 
inﬂ  ammatory markers in the EBC serially over 60 days in 
patients hospitalized with AECOPD. We have shown that the 
TNF-α level in EBC was lower on Day 5 post-hospitalization 
for AECOPD when compared to the levels on Day 14, 
Day 30, and Day 60. The lower TNF-α level on Day 5 was 
likely secondary to the anti-inﬂ  ammatory effect of systemic 
steroid and antibiotic. In contrast, there was no signiﬁ  cant 
change in the serial LTB4 levels in EBC. Repeatability 
measurements of TNF-α and LTB4 among our stable 
COPD patients were satisfactory. Interestingly, the subjects 
receiving ICS had a lower EBC TNF-α level at Day 60 post-
hospitalization for AECOPD than those not on ICS treatment. 
Previous studies have either measured EBC biomarkers at 
the start of exacerbation and compared against stable COPD 
and normal subjects (Gessner et al 2005), or measured the 
level of biomarkers serially during the ﬁ  rst week of AECOPD 
(Gerritsen et al 2005; Oudijk et al 2006).
As our patients were dyspneic on admission to hospital, 
EBC assessment was only commenced on Day 5 when they 
became more stable and able to comply with EBC collec-
tion. Ideally, systemic steroids should have been withheld 
as it could suppress inﬂ  ammation in the airway. As previous 
studies (Davies et al 1999; Wood-Baker et al 2005) have 
consistently shown that systemic steroid can reduce treat-
ment failure and need for additional medical treatment in 
subjects with severe AECOPD, we felt that it was unethical 
to withhold the therapy, which was strongly recommended 
in the GOLD Guideline (National Heart, Lung and Blood 
Institute, World Health Organization 2006), for research 
purposes.
Table 3 Levels of the biomarkers
TNF-α (pg/ml) LTB4 (pg/ml)
AECOPD Day 5 5.08 (3.80–6.32) 6.30 (5.17–8.07)
AECOPD Day 14 5.84 (4.91–9.14)* 6.47 (5.05–8.00)
AECOPD Day 30 6.14 (3.82–7.67)* 6.26 (4.70–7.99)
AECOPD Day 60 5.60 (4.53–8.80)* 5.77 (4.82–7.37)
Stable COPD 5.39 (3.80–6.89) 5.90 (5.21–7.10)
Normal controls 4.84 (3.86–5.81)** 5.80 (5.29–7.54)
Notes: Data were presented in median (IQR); *p   0.05 when compared with the 
level of biomarker at Day 5;  **p = 0.036 when comparing levels of biomarker between 
control subjects and Day 14 post-hospitalization for patients with AECOPD.
Abbreviations: AECOPD, acute exacerbations of chronic obstructive pulmonary 
disease; LTB4, leukotriene B4;   TNF-α, tumor necrosis factor-α.
Table 2 Detection rates of   TNF-α, LTB4 and IL-8 in exhaled 
breath condensate
TNF-α (pg/ml) LTB4(pg/ml) IL-8(pg/ml)
  n (%) n (%) n (%)
AECOPD Day 5 26 (100) 23 (89) 1 (4)
AECOPD Day 14 26 (100) 26 (100) 4 (15)
AECOPD Day 30 26 (100) 25 (96) 3 (12)
AECOPD Day 60 26 (100) 25 (96) 2 (8)
Stable COPD 11 (100) 9 (82) 0 (0)
Normal controls 14 (100) 14 (100) 2 (14)
Abbreviations: AECOPD, acute exacerbations of chronic obstructive pulmonary 
disease; IL-8, interleukin-8; LTB4, leukotriene B4; TNF-α, tumor necrosis factor-α.International Journal of COPD 2009:4 83
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Previous studies have found that TNF-α level was raised 
in both EBC (Gessner et al 2005) and sputum (Aaron et al 
2001) of subjects with AECOPD. However, the changes 
in circulating levels of TNF-α during AECOPD were less 
consistent. Some studies showed that its level correlated 
negatively with the changes in FEV1 during the exacerba-
tion (Pinto-Plata et al 2007), whereas others reported no 
change when comparing the stable baseline level with the 
AECOPD level (Hurst et al 2006). It is interesting to note that 
the level of TNF-α was similar from Day 14 onwards dur-
ing the course of AECOPD in our study. It remains unclear 
why the TNF-α level was similar between the stable state 
COPD and the normal healthy controls. A previous study 
has suggested that markers such as LTB4 and 8-isoprostane 
might take 2 months to return to normal state with antibiotic 
(without systemic steroid) treatment (Biernacki et al 2003). 
The 1-week course of systemic steroid administered to our 
patients with AECOPD has possibly sped up the recovery 
of TNF-α.
TNF-α could be measured in the EBC in every subject 
in this current study, and similar observation was noted in 
our previous study involving asthmatic subjects (Leung et al 
2005). This ﬁ  nding was also consistent with another study 
assessing TNF-α in EBC using cytometric bead array rather 
than ELISA (Gessner et al 2005). Our level of TNF-α was 
lower than that measured by cytometric bead array assay and 
this might be explained by the different methods of biomarker 
measurement (Gessner et al 2005). An experimental study 
with animal models showed that over-expression of TNF-α 
induced the pathological changes similar to emphysema 
and pulmonary ﬁ  brosis (Lundblad et al 2005). It is likely 
that TNF-α plays an important role in the pathogenesis of 
COPD and its level may be altered during the course of 
AECOPD.
We have noted that TNF-α level was lower in the EBC 
on Day 60 post-hospitalization for AECOPD in subjects who 
were on ICS therapy than those who were not. A previous 
study has shown that some cytokines in EBC such as IL-1β, 
IL-6, IL-8, IL-12, and IL-10, but not TNF-α, were lower in 
stable COPD patients on ICS compared to those who were not 
on this therapy (Gessner et al 2005). Induced sputum study 
also failed to show the effect of ICS therapy on TNF-α or 
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Figure 1 Levels of TNF-α in the subjects with AECOPD, stable COPD and normal controls
Abbreviations: AECOPD, acute exacerbations of chronic obstructive pulmonary disease; COPD, chronic obstructive pulmonary disease; TNF-α, tumor necrosis factor-α.
Table 4 Serial spirometry results of the subjects with acute exac-
erbation of COPD (n = 26)
  Day 5 Day 14 Day 30 Day 60
FEV1% predicted 41.5 ± 12.9 46.1 ± 14.2 43.6 ± 14.2 44.5 ± 14.6
FVC% predicted 54.8 ± 17.8 61.5 ± 20.5 61.7 ± 18.2 62.1 ± 19.0
FEV1/FVC (%) 57.0 ± 12.3 56.1 ± 12.0 52.8 ± 11.8 53.4 ± 11.6
FEV1 (L) 0.83 ± 0.29 0.91 ± 0.28 0.89 ± 0.37 0.91 ± 0.62
FVC (L) 1.54 ± 0.56 1.66 ± 0.56 1.72 ± 0.59 1.74 ± 0.62
Note: Data were presented as mean ± SD.
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital 
capacity.International Journal of COPD 2009:4 84
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other inﬂ  ammatory indices in the sputum of COPD patients 
(Keatingset al 1997). Several studies have suggested that 
ICS could reduce the frequency of AECOPD in subjects with 
severe COPD (Burge et al 2000). Whether TNF-α or other 
biomarkers are involved in the mechanisms of AECOPD will 
require further exploration.
LTB4 in the COPD airway is likely mediating its effects 
via activation of neutrophils. Assessment of chemotactic 
activity of LTB4 during AECOPD using the LTB4 receptor 
antagonist LY293111 revealed that LTB4 contributed 
signiﬁ  cantly (∼30%) to neutrophil inﬂ  ux into the airway 
in COPD subjects (Crooks et al 2000). A previous study 
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Figure 2 Bland and Altman’s plot of the repeatability measurements of TNF-α and LTB4.
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found that LTB4 level in EBC was higher in COPD patients 
(for both steroid naïve and those on ICS) than among controls 
(Montuschi et al 2003). In our study, the changes in the level 
of LTB4 were not apparent during the course of AECOPD 
and this might be related to the treatment with both systemic 
steroid and antibiotic. IL-8 was not measurable in the major-
ity of the EBC samples in this study. Previous studies on 
IL-8 in the airway have been inconclusive. One study found 
no difference in the IL-8 level in induced sputum specimen 
in subjects with stable or AECOPD (Bhowmik et al 2000), 
whereas Gessner and colleagues noted that EBC IL-8 level 
was higher in subjects with AECOPD admitted to the general 
ward or to the intensive care unit for mechanical ventilation 
(Gessner et al 2005). Studies on serum IL-8 level in patients 
with AECOPD treated with systemic steroid showed a gradual 
fall in its level in the ﬁ  rst 7 days of the AECOPD (Gerritsen 
et al 2005). It is uncertain why we could not measure IL-8 
reliably in our study. In the study by Gessner and colleagues, 
the IL-8 level, measured by the multiplex ﬂ  uorescent bead 
immunoassay cytometric bead array technique, was well 
above the detection limit of the ELISA kit used in our current 
study, despite the fact that their levels of IL-8 in the stable 
COPD patients and controls were also quite low (Gessner 
et al 2005). It is possible that we might have missed the peak 
of IL-8 at the start of the AECOPD and thus could not detect 
any IL-8 after 5-days of systemic steroid.
The limitations of this study included a relatively small 
sample size and the ex-smoker status of the subjects was 
not confirmed objectively by urine cotinine assay. As 
smoking may affect EBC markers, we did not include active 
smokers in this study (Gessner et al 2005; Carpagnano 
et al 2003; Gareyet al 2004). Ideally age- and sex-matched 
ex-smokers with normal lung function would serve as better 
controls than nonsmoking age and sex-matched subjects. 
In addition, we had not collected baseline EBC samples 
before AECOPD and thus the levels of biomarkers before 
therapy were unknown. Though the repeatability test of 
the TNF-α and LTB4 appeared satisfactory, as reﬂ  ected by 
the differences between most of the paired measurements 
laying within   ±  2SDs (Figure 2), the relatively large SD 
values when compared to the absolute measured values of 
TNF-α and LTB4 would warrant cautions when interpret-
ing the results. EBC assessment is still a relatively new tool 
in respiratory research with many methodological pitfalls 
(Effros et al 2004; Horvathet al 2005), including the vari-
ability of the measurement and the low concentrations of 
mediators measured (Effros et al 2004; Horvathet al 2005). 
There are suggestions that biomarker concentrations depend 
on other factors such as the dilution of the samples (Effros 
et al 2004; Horvathet al 2005). Adjusting the concentrations 
using dilutional indicator (eg, conductivity of lyonphized 
EBC) in future studies may improve the accuracy of EBC 
measurement. As many factors were interplaying that could 
affect the levels of biomarkers (eg, the assay method of the 
biomarkers and the treatment given during the exacerbations), 
it is difﬁ  cult to conclude whether the changes in the levels of 
the biomarkers were, in fact, due to “cause and effect” with 
respect to exacerbations and remissions.
Conclusion
In conclusion, it is feasible to obtain serial EBC in patients 
following AECOPD. EBC TNF-α level was lower on Day 5 
post-hospitalization for AECOPD than the levels at other time 
points up to 60 days, and this was likely due to the effect 
of treatment with systemic steroid and antibiotic. The level 
of LTB4 did not change signiﬁ  cantly during the course of 
AECOPD whereas IL-8 was mostly undetectable in the EBC. 
Research in EBC is a constantly evolving ﬁ  eld and more 
sensitive assays and novel biomarkers may be identiﬁ  ed in 
the future (Barnes et al 2006). As in the case of measuring 
exhaled nitric oxide level in asthma management (Smith et al 
2005), prospective randomized trials are needed to evaluate 
if the measurement of TNF-α in EBC may guide treatment 
and improve outcome in patients with COPD.
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